about
Circulating soluble Fas levels and risk of ovarian cancerRecent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data.The advantage of women in cancer survival: an analysis of EUROCARE-4 data.Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.Measuring cancer prevalence in Europe: the EUROPREVAL project.Cancer survival in five continents: a worldwide population-based study (CONCORD).Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.Socio-economic factors and health care system characteristics related to cancer survival in the elderly. A population-based analysis in 16 European countries (ELDCARE project).Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.Cancer rehabilitation indicators for Europe.A method for differentiating cancer prevalence according to health status, exemplified using a population-based sample of Italian colorectal cancer cases.Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study.Testosterone and biological characteristics of breast cancers in postmenopausal women.Plasma retinol and prognosis of postmenopausal breast cancer patients.Circulating levels of sex steroid hormones and risk of ovarian cancer.Use of socio-economic factors and healthcare resources to estimate cancer survival in European countries with partial national cancer registration.Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women.Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women.Endogenous sex hormones and subsequent breast cancer in premenopausal women.Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort.Erythrocyte membrane phospholipid composition as a biomarker of dietary fat.European health systems and cancer care.Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas.Cancer prevalence in the UK: results from the EUROPREVAL study.EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.Survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. The EUROCARE Working Group.The cure for colon cancer: results from the EUROCARE study.Serum sex hormone levels after menopause and subsequent breast cancer.Recent trends of cancer mortality in Romanian adults: mortality is still increasing, although young adults do better than the middle-aged and elderly population.Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy).Cancer survival increases in Europe, but international differences remain wide.A wide difference in cancer survival between middle aged and elderly patients in Europe.Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer.Re: Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer Among Premenopausal WomenCirculating enterolactone and risk of endometrial cancerIGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studiesBody mass index in relation to ovarian cancer: A multi-centre nested case-control studyCancer prevalence in European registry areasCirculating levels of insulin-like growth factor-I and risk of ovarian cancer
P50
Q24805356-4E0B55D2-326D-4E50-A605-95AE2066778AQ31122446-B08CE336-DF2D-411D-B54F-6DDE4A95729EQ33395907-90894A9A-2AC3-4B00-8F1D-8CC7D191B40DQ33722863-A630E03F-DB89-480C-9AF9-FB091FB86C6AQ34512957-8ABCABE1-7275-4339-BAA2-C33BE0384A11Q34746939-981D9324-AFA3-471D-9CA7-26A1987EC201Q34798041-FD02262C-B98B-4C84-9F75-19E0FFA9E00FQ35287715-73067827-F28A-4797-B7B2-33AF1C90F903Q36103266-4100ED08-9485-4F5E-91E6-504D3B358846Q37071422-BBE6F8FC-14E4-42C3-9E52-35A7DE08E90AQ38398998-AD0A8435-B313-4C9F-87A0-25EBB3C9A3DAQ38399132-4C52B313-C64F-4040-98A1-13434D936B10Q40220309-33FCA83C-6E0D-482B-B9D4-01357B2C389CQ43258114-5E21D425-C036-4462-9F56-40E4AEE2D8F7Q43481052-D039296C-ACFC-417C-86F3-277F5FDC22CBQ43485500-03009577-1388-4011-A205-58785BDCBAF8Q44210664-6226E575-1AA1-4B4C-BEA3-D91B928901FFQ44675827-88618643-26D3-4F4A-AF99-14CE40747D59Q44756438-1275788C-44E3-483E-9684-16BCDA61C64DQ45047695-431D85E3-0A17-421E-AE13-D8B15A3A4884Q46174510-DCEA1864-F8B1-4AC8-88C3-0860B464886FQ46865089-64B0B6BE-75D1-4627-A822-F545FBBF27A1Q47310239-A8316AAB-C181-4352-B7FD-7CBEF6BFE417Q47310250-61E090D6-0892-421B-9AF0-E588E62CE142Q48022352-D9FC0580-3120-4A00-BBE1-616336D9EF83Q48111201-9F5F8C26-F332-4C0C-8566-B3414F8EE26AQ50872622-192B3D00-CCE1-42FE-BE0B-40721879AB3DQ50876704-C3BE2347-516B-4DAA-8009-723FD06ACC35Q51035256-7A967472-9383-4325-ACE2-96EC7B1E7A39Q51192421-CEB0E6AB-0D4F-4B1E-8C67-6BF91C15803BQ51535871-6D5598E2-CA9F-4FC4-8455-45D00D364AF0Q53322613-E6E7C4F8-CE6D-40C1-A871-29F43E597477Q54364945-8C2E543A-045A-4E6B-92CA-F6A8AA465379Q55037918-0A766A9D-D024-44E4-9495-F8327E7C7804Q57037739-32759CF3-59B2-4D5D-9215-7C62C5F3BEE2Q57037766-CE1EFEB8-E0E4-48BC-AFB3-C1DAF25FA2AEQ57037834-B5BD4FC0-383D-419A-BB9E-87F46E1C557AQ57037899-36C7D2A1-E4E2-4B4B-83D3-C3E169B43764Q57037907-F9513022-C503-4470-879C-27D2C928DE3FQ57037912-1EB352CB-DE0D-42ED-B4FF-471CBE4DE2BC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrea Micheli
@ast
Andrea Micheli
@en
Andrea Micheli
@es
Andrea Micheli
@nl
type
label
Andrea Micheli
@ast
Andrea Micheli
@en
Andrea Micheli
@es
Andrea Micheli
@nl
prefLabel
Andrea Micheli
@ast
Andrea Micheli
@en
Andrea Micheli
@es
Andrea Micheli
@nl
P214
P2163
P244
P106
P1153
7005491436
P213
0000 0000 7875 4487
P214
P2163
P244
nr2002034789
P31
P396
IT\ICCU\TO0V\332782
P496
0000-0002-4558-4754
P569
1972-01-01T00:00:00Z
P734
P735
P7859
lccn-nr2002034789